The global Dry Age Related Macular Degeneration Amd Market is entering a period of significant expansion, driven primarily by the demographic reality of a rapidly aging worldwide population. With dry AMD accounting for approximately 85-90% of all macular degeneration cases, the massive patient pool—estimated at over 64 million across the seven major markets in 2023—presents a substantial commercial opportunity that has galvanized pharmaceutical and biotech companies. Market valuation is projected to more than double in the coming decade, reflecting the urgent and unmet medical need for effective treatments beyond the current standard of care, which historically centered on AREDS2 nutritional supplements and lifestyle modifications. Recent advancements, particularly the FDA approval of novel complement inhibitors to slow the progression of geographic atrophy (GA), have injected fresh optimism and competition into this space. North America currently dominates the market share due to high healthcare expenditure and a large geriatric demographic, though the Asia-Pacific region is poised for the fastest growth, fueled by its own rapidly aging citizenry and increasing healthcare access.

This robust market growth, projected at a CAGR exceeding 7%, is further bolstered by rising healthcare spending and governmental initiatives supporting ophthalmic research and development. The commercialization of the first-ever treatments for geographic atrophy—the late stage of dry AMD—has validated a path to market for other pipeline candidates. Companies are now keenly focused on developing next-generation therapies, including gene therapy, stem cell treatments, and oral medications, which promise less invasive and more convenient options for patients. The market's future will be defined by the success of these novel platforms in addressing the underlying pathology of the disease.